SAR125844(选择性MET酪氨酸激酶抑制剂)在MET扩增晚期实体瘤患者中的首次人体I期研究
该I期研究评估了高选择性MET抑制剂SAR125844在MET失调晚期实体瘤患者中的安全性及初步疗效。研究采用3+3剂量递增(50-740 mg/m2)和剂量扩展设计,确定最大耐受剂量(MTD)为570 mg/m2,每周一次静脉给药。在MET扩增患者中观察到部分缓解,尤其非小细胞肺癌(NSCLC)患者,且耐受性良好。
要点
- SAR125844每周一次静脉给药的MTD为570 mg/m2。
- 常见不良事件为乏力/疲劳、恶心、腹痛、便秘和呼吸困难。
- MET扩增患者中可见部分缓解,包括NSCLC患者。
核心结论
- SAR125844每周一次给药的MTD为570 mg/m2,耐受性良好,在MET扩增NSCLC患者中具有显著抗肿瘤活性。
研究设计与样本
- I期剂量递增(3+3设计,50-740 mg/m2)和剂量扩展研究,共纳入72例患者(剂量递增33例,剂量扩展39例)。
主要发现
- 最常见治疗中出现的不良事件为乏力/疲劳(58.3%)、恶心(31.9%)、腹痛、便秘和呼吸困难(各27.8%)。
- 58.3%的患者报告3级不良事件,其中19.4%与治疗相关。
- 在570 mg/m2剂量下可评估的29例MET扩增患者中,5例达到部分缓解,包括22例NSCLC中的4例;17例疾病稳定。
- 高p-MET表达实体瘤患者中未观察到缓解。
- 肿瘤缓解与t-MET状态或MET基因拷贝数无相关性。
关键数值与推荐
- MTD为570 mg/m2(每周一次静脉给药)。
- 剂量递增阶段患者需IHC检测高总MET(t-MET)表达或FISH检测MET扩增;剂量扩展阶段患者需MET扩增(包括NSCLC亚组)或IHC检测p-MET表达。
临床怎么用
- SAR125844在MET扩增的晚期实体瘤患者中显示出初步抗肿瘤活性,尤其NSCLC患者,支持进一步研究。
局限性
- 样本量较小,结果为初步性,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation. METHODS: This was a phase I dose-escalation (3 + 3 design [50-740 mg/m2]) and dose-expansion study. In the dose escalation, patients had high total MET (t-MET) expression by immunohistochemistry (IHC) or MET amplification by fluorescence in situ hybridisation. In the dose expansion, patients had MET amplification (including a subset of patients with non-small cell lung cancer [NSCLC]) or phosphorylated-MET (p-MET) expression (IHC). Objectives were determination of maximum tolerated dose (MTD) of once-weekly intravenous SAR125844 based on dose-limiting toxicities; safety and pharmacokinetic profile; preliminary efficacy of SAR125844 MTD in the expansion cohort. RESULTS: In total, 72 patients were enrolled: dose escalation, N = 33; dose expansion, N = 39; 570 mg/m2 was established as the MTD. Most frequent treatment-emergent adverse events (AEs) were asthenia/fatigue (58.3%), nausea (31.9%), and abdominal pain, constipation, and dyspnea (27.8% for each); 58.3% of patients reported grade 3 AEs (19.4% were treatment related). Of the 29 evaluable patients with MET amplification treated at 570 mg/m2, five achieved a partial response, including four of 22 with NSCLC; 17 patients had stable disease. No response was observed in patients with high p-MET solid tumours. There was no correlation between tumour response and t-MET status or MET gene copy number. CONCLUSION: The MTD of once-weekly SAR125844 was 570 mg/m2; SAR125844 was well tolerated, with significant antitumour activity in patients with MET-amplified NSCLC. CLINICAL TRIAL REGISTRATION NUMBER: NCT01391533.
引用
- Angevin E, Spitaleri G, Rodon J, et al. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur J Cancer. 2017. PMID: 29145039. doi:10.1016/j.ejca.2017.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。